Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 6/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.35 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29380978 | 1.00 | MAPT (0.41) | MAPTSMN1; SMN2L3MBTL1ACHENR4A2 | |
| Trifluoromethanesulfonic Acid SCHEMBL38665301 | 0.91 | MAPT (0.39) | MAPTSMN1; SMN2L3MBTL1ACHENR4A2 | |
| Trifluoromethanesulfonic Acid SCHEMBL5705540 | 0.91 | MAPT (0.39) | MAPTSMN1; SMN2L3MBTL1ACHENR4A2 | |
| SCHEMBL29349846 | 0.90 | ACHE (0.44) | MAPTSMN1; SMN2L3MBTL1ACHENR4A2 | |
| SCHEMBL8491878 | 0.90 | ACHE (0.44) | MAPTSMN1; SMN2L3MBTL1ACHENR4A2 | |
| SCHEMBL4749617 | 0.86 | MAPT (0.39) | MAPTSMN1; SMN2L3MBTL1NR4A2RAB9A | |
| SCHEMBL9426549 | 0.85 | TERT (0.35) | MAPTSMN1; SMN2L3MBTL1ACHERAB9A | |
| SCHEMBL3907421 | 0.83 | L3MBTL1 (0.36) | MAPTSMN1; SMN2L3MBTL1ACHEHPGD | |
| Trifluoromethanesulfonic Acid SCHEMBL4804620 | 0.83 | KCNH2 (0.36) | MAPTSMN1; SMN2L3MBTL1ACHEHPGD | |
| Trifluoromethanesulfonic Acid SCHEMBL4798225 | 0.83 | KCNH2 (0.41) | MAPTACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 434 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116660543-A | Diagnostic and prognostic markers for nonalcoholic fatty liver disease and uses thereof | 中国人民解放军陆军军医大学第一附属医院 | 2023-08-29 | — | — | CN | claimed |
| EP-0330433-B1 | Protected chemiluminescent labels | GEN PROBE INC (US) | 1996-04-17 | — | — | EP | claimed |
| JP-8000292-A | — | — | None | — | — | JP | disclosed |
| EP-4729943-A2 | IMPROVED METHODS OF ASSESSING GFAP STATUS IN PATIENT SAMPLES | Abbott Laboratories (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260072042-A1 | METHODS FOR AIDING IN DIAGNOSING AND EVALUATING A TRAUMATIC BRAIN INJURY IN A HUMAN SUBJECT USING A COMBINATION OF GFAP AND UCH-L1 | ABBOTT LAB (US) | 2026-03-12 | — | — | US | disclosed |
| EP-4697023-A2 | METHODS FOR AIDING IN THE HYPERACUTE DIAGNOSIS AND DETERMINATION OF TRAUMATIC BRAIN INJURY IN A HUMAN SUBJECT USING EARLY BIOMARKERS | Abbott Laboratories (US) | 2026-02-18 | — | — | EP | disclosed |
| EP-3519825-B1 | IMPROVED METHODS OF ASSESSING GFAP STATUS IN PATIENT SAMPLES | ABBOTT LAB (US) | 2025-11-19 | — | — | EP | disclosed |
| EP-3732489-B1 | NOVEL BIOMARKERS AND METHODS FOR DIAGNOSING AND EVALUATING TRAUMATIC BRAIN INJURY | ABBOTT LAB (US) | 2025-10-22 | — | — | EP | disclosed |
| EP-3610268-B1 | METHODS FOR AIDING IN THE HYPERACUTE DIAGNOSIS AND DETERMINATION OF TRAUMATIC BRAIN INJURY IN A HUMAN SUBJECT USING EARLY BIOMARKERS | ABBOTT LAB (US) | 2025-09-24 | — | — | EP | disclosed |
| EP-3635407-B1 | METHODS FOR AIDING IN THE HYPERACUTE DIAGNOSIS AND DETERMINATION OF TRAUMATIC BRAIN INJURY USING EARLY BIOMARKERS ON AT LEAST TWO SAMPLES FROM THE SAME HUMAN SUBJECT | ABBOTT LAB (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250185979-A1 | METHODS FOR AIDING IN DIAGNOSING AND EVALUATING A MILD TRAUMATIC BRAIN INJURY IN A HUMAN SUBJECT USING CARDIAC TROPONIN I | THE JOHNS HOPKINS UNIVERSITY | 2025-06-12 | — | — | US | disclosed |
| WO-2009131963-A2 | METHOD AND KIT FOR ASSESSING THE SUITABILITY OF ERYTHROCYTES FOR TRANSFUSION | ABBOTT LABORATORIES (US) | 2009-10-29 | — | — | WO | disclosed |
| US-20090263845-A1 | METHOD AND KIT FOR ASSESSING THE SUITABILITY OF ERYTHROCYTES FOR TRANSFUSION | ABBOTT LABORATORIES (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090162876-A1 | MYELOPEROXIDASE ASSAYS | ABBOTT LABORATORIES (US) | 2009-06-25 | — | — | US | disclosed |
| WO-2009076330-A1 | STABILIZING COMPOSITIONS, METHODS AND KITS FOR CHEMILUMINESCENT ASSAYS | ABBOTT LABORATORIES (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090148879-A1 | Stabilizing Compositions, Methods and Kits for Chemiluminescent Assays | ABBOTT LABORATORIES | 2009-06-11 | — | — | US | disclosed |
| WO-2008124749-A1 | ACRIDINIUM PHENYL ESTERS USEFUL IN THE ANALYSIS OF BIOLOGICAL SAMPLES | ABBOTT LABORATORIES (US) | 2008-10-16 | — | — | WO | disclosed |
| US-20080248493-A1 | ACRIDINIUM PHENYL ESTERS USEFUL IN THE ANALYSIS OF BIOLOGICAL SAMPLES | ABBOTT LABORATORIES | 2008-10-09 | — | — | US | disclosed |
| US-5790627-A | Method and apparatus for observing a specimen using an X-ray microscope | RESEARCH DEVELOPMENT CORP. (JP) | 1998-08-04 | — | — | US | disclosed |
| JP-H08292-A | METHOD FOR EMISSION OF ACRIDINIUM DERIVATIVE AND DETECTION OF SUBJECT SUBSTANCE FOR INSPECTION BY THE SAME METHOD | IATRON LAB INC | 1996-01-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260072042-A1 | METHODS FOR AIDING IN DIAGNOSING AND EVALUATING A TRAUMATIC BRAIN INJURY IN A HUMAN SUBJECT USING A COMBINATION OF GFAP AND UCH-L1 | UCHL1, UCHL3, UCHL5 | MAPT 187/4885SMN1; SMN2 1289/4885L3MBTL1 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.